Literature DB >> 29461924

Controlling alpha for mixed effects models for repeated measures.

Zhishen Ye1, B Nebiyou Bekele1.   

Abstract

Mixed Effects Models for Repeated Measures (MMRM) is often used in clinical trials with longitudinal data. However, there has not been an in-depth examination available on how investigators can implement interim analysis while also controlling the overall alpha for clinical trials under an MMRM analysis framework. Statistical independence among measurements, which is often assumed in group sequential testing (GST), is not valid under an MMRM framework due to the correlations induced by longitudinal within-subject measurements. Therefore, methods associated with GST derived under independence need to be adjusted accordingly. While these correlations can be estimated from the study data, regulatory agencies may not accept results based on these estimated correlations since there is no guarantee that the overall alpha is strongly controlled. In this article, we propose a new AC-Hybrid-approach for controlling the overall alpha. The AC-Hybrid-approach has two key attributes. First, we apply the MMRM analysis framework on all available data at every analysis timepoint. Second, we use complete-case information fractions to derive the group sequential stopping boundaries. We prove that the overall alpha is controlled regardless of the correlations among within-subject measurements. We also show the impact of this approach on the alpha and the power through examples.

Keywords:  Alpha control; MMRM; clinical trials; group sequential testing; interim analysis

Mesh:

Substances:

Year:  2018        PMID: 29461924     DOI: 10.1080/10543406.2018.1439052

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  1 in total

1.  Modelling strawberry quality in a longitudinal study under the marketing concept of branding.

Authors:  Thais Mendes da Silva; Nicole Roberta Giuggioli; Cristiana Peano
Journal:  Heliyon       Date:  2021-02-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.